Cargando…

Orthogonal immunoassays for IgG antibodies to SARS-CoV-2 antigens reveal that immune response lasts beyond 4 mo post illness onset

Immune response to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection during the current pandemic remains a field of immense interest and active research worldwide. Although the severity of acute infection may depend on the intensity of innate and adaptive immunity, leading to hi...

Descripción completa

Detalles Bibliográficos
Autores principales: Sasisekharan, Varun, Pentakota, Niharika, Jayaraman, Akila, Tharakaraman, Kannan, Wogan, Gerald N., Narayanasami, Uma
Formato: Online Artículo Texto
Lenguaje:English
Publicado: National Academy of Sciences 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7865175/
https://www.ncbi.nlm.nih.gov/pubmed/33446512
http://dx.doi.org/10.1073/pnas.2021615118
_version_ 1783647787415502848
author Sasisekharan, Varun
Pentakota, Niharika
Jayaraman, Akila
Tharakaraman, Kannan
Wogan, Gerald N.
Narayanasami, Uma
author_facet Sasisekharan, Varun
Pentakota, Niharika
Jayaraman, Akila
Tharakaraman, Kannan
Wogan, Gerald N.
Narayanasami, Uma
author_sort Sasisekharan, Varun
collection PubMed
description Immune response to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection during the current pandemic remains a field of immense interest and active research worldwide. Although the severity of acute infection may depend on the intensity of innate and adaptive immunity, leading to higher morbidity and mortality, the longevity of IgG antibodies, including neutralizing activity to SARS-CoV-2, is viewed as a key correlate of immune protection. Amid reports and concern that there is a rapid decay of IgG antibody levels within 1 mo to 2 mo after acute infection, we set out to study the pattern and duration of IgG antibody response to various SARS-CoV-2 antigens in asymptomatic and symptomatic patients in a community setting. Herein, we show the correlation of IgG anti-spike protein S1 subunit, receptor binding domain, nucleocapsid, and virus neutralizing antibody titers with each other and with clinical features such as length and severity of COVID-19 illness. More importantly, using orthogonal measurements, we found the IgG titers to persist for more than 4 mo post symptom onset, implying that long-lasting immunity to COVID-19 from infection or vaccination might be observed, as seen with other coronaviruses such as SARS and Middle East respiratory syndrome.
format Online
Article
Text
id pubmed-7865175
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher National Academy of Sciences
record_format MEDLINE/PubMed
spelling pubmed-78651752021-02-17 Orthogonal immunoassays for IgG antibodies to SARS-CoV-2 antigens reveal that immune response lasts beyond 4 mo post illness onset Sasisekharan, Varun Pentakota, Niharika Jayaraman, Akila Tharakaraman, Kannan Wogan, Gerald N. Narayanasami, Uma Proc Natl Acad Sci U S A Biological Sciences Immune response to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection during the current pandemic remains a field of immense interest and active research worldwide. Although the severity of acute infection may depend on the intensity of innate and adaptive immunity, leading to higher morbidity and mortality, the longevity of IgG antibodies, including neutralizing activity to SARS-CoV-2, is viewed as a key correlate of immune protection. Amid reports and concern that there is a rapid decay of IgG antibody levels within 1 mo to 2 mo after acute infection, we set out to study the pattern and duration of IgG antibody response to various SARS-CoV-2 antigens in asymptomatic and symptomatic patients in a community setting. Herein, we show the correlation of IgG anti-spike protein S1 subunit, receptor binding domain, nucleocapsid, and virus neutralizing antibody titers with each other and with clinical features such as length and severity of COVID-19 illness. More importantly, using orthogonal measurements, we found the IgG titers to persist for more than 4 mo post symptom onset, implying that long-lasting immunity to COVID-19 from infection or vaccination might be observed, as seen with other coronaviruses such as SARS and Middle East respiratory syndrome. National Academy of Sciences 2021-02-02 2021-01-14 /pmc/articles/PMC7865175/ /pubmed/33446512 http://dx.doi.org/10.1073/pnas.2021615118 Text en Copyright © 2021 the Author(s). Published by PNAS. http://creativecommons.org/licenses/by/4.0/ https://creativecommons.org/licenses/by/4.0/This open access article is distributed under Creative Commons Attribution License 4.0 (CC BY) (http://creativecommons.org/licenses/by/4.0/) .
spellingShingle Biological Sciences
Sasisekharan, Varun
Pentakota, Niharika
Jayaraman, Akila
Tharakaraman, Kannan
Wogan, Gerald N.
Narayanasami, Uma
Orthogonal immunoassays for IgG antibodies to SARS-CoV-2 antigens reveal that immune response lasts beyond 4 mo post illness onset
title Orthogonal immunoassays for IgG antibodies to SARS-CoV-2 antigens reveal that immune response lasts beyond 4 mo post illness onset
title_full Orthogonal immunoassays for IgG antibodies to SARS-CoV-2 antigens reveal that immune response lasts beyond 4 mo post illness onset
title_fullStr Orthogonal immunoassays for IgG antibodies to SARS-CoV-2 antigens reveal that immune response lasts beyond 4 mo post illness onset
title_full_unstemmed Orthogonal immunoassays for IgG antibodies to SARS-CoV-2 antigens reveal that immune response lasts beyond 4 mo post illness onset
title_short Orthogonal immunoassays for IgG antibodies to SARS-CoV-2 antigens reveal that immune response lasts beyond 4 mo post illness onset
title_sort orthogonal immunoassays for igg antibodies to sars-cov-2 antigens reveal that immune response lasts beyond 4 mo post illness onset
topic Biological Sciences
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7865175/
https://www.ncbi.nlm.nih.gov/pubmed/33446512
http://dx.doi.org/10.1073/pnas.2021615118
work_keys_str_mv AT sasisekharanvarun orthogonalimmunoassaysforiggantibodiestosarscov2antigensrevealthatimmuneresponselastsbeyond4mopostillnessonset
AT pentakotaniharika orthogonalimmunoassaysforiggantibodiestosarscov2antigensrevealthatimmuneresponselastsbeyond4mopostillnessonset
AT jayaramanakila orthogonalimmunoassaysforiggantibodiestosarscov2antigensrevealthatimmuneresponselastsbeyond4mopostillnessonset
AT tharakaramankannan orthogonalimmunoassaysforiggantibodiestosarscov2antigensrevealthatimmuneresponselastsbeyond4mopostillnessonset
AT wogangeraldn orthogonalimmunoassaysforiggantibodiestosarscov2antigensrevealthatimmuneresponselastsbeyond4mopostillnessonset
AT narayanasamiuma orthogonalimmunoassaysforiggantibodiestosarscov2antigensrevealthatimmuneresponselastsbeyond4mopostillnessonset